Angioflux, 600 units, 2 ml, 10 pcs.

An anticoagulant agent, heparinoid. It has antiaggregant, antithrombotic, angioprotective, hypolipidemic and fibrinolytic effect. The active substance is an extract from the mucous membrane of small intestine of animals and is a natural mixture of fast-moving heparin-like fraction (80%) and dermatan-sulfate (20%).

Suppresses activated factor X, increases the synthesis and secretion of prostacyclin (prostaglandin PgI2), reduces the concentration of plasma fibrinogen. Increases the concentration of the activator of tissue profibrinolysin (plasminogen) in blood and decreases the blood concentration of its inhibitor.

The mechanism of angioprotective action is associated with restoration of structural and functional integrity of vascular endothelial cells, as well as the normal density of the negative electric charge of pores of the basal membrane of vessels. Normalizes rheological properties of blood by reducing TG and decreasing blood viscosity.

The efficacy of use in diabetic nephropathy is determined by reduction of basal membrane thickness and decrease of matrix production due to decrease of mesangium cell proliferation.

Indications

Diabetic retinopathy, Vascular lesions in diabetes, Thrombosis prevention, Diabetic nephropathy

• Angiopathies with an increased risk of thrombosis, including:
  • After myocardial infarction.
• Brain Circulatory Disorders, including acute ischemic Stroke and early recovery period.
• Discirculatory encephalopathy due to:
  • Atherosclerosis.
  • Diabetes mellitus.
  • Arterial hypertension.
• Vascular dementia.
• Occlusive lesions of peripheral arteries, including:
  • Atherosclerotic genesis.
  • Diabetic genesis.
• Phlebopathies, deep vein thrombosis.
• Microangiopathies:
  • Nephropathy.
  • Retinopathy.
  • Neuropathy.
• Macroangiopathies in diabetes:
  • Diabetic foot syndrome.
  • Encephalopathy.
  • Cardiopathy.
• In combination therapy with acetylsalicylic acid:
  • Trombotic conditions.
  • Antiphospholipid syndrome.
• To continue therapy in the development of heparin-induced thrombocytopenia.

.

Active ingredient

Sulodexide

Composition

Active ingredient:

sulodexide 300 IU.

How to take, the dosage

Intravenously (bolus or drip) or intramuscularly, 2 ml (1 ampoule) per day.

For intravenous drip administration the drug is pre-diluted in 150-200 ml of 0.9% sodium chloride solution.

The treatment is recommended to begin with parenteral administration of the drug for 15-20 days, after which the capsules are taken for 30-40 days.

The full course of treatment is carried out 2 times a year.

The course length and dose of the drug may vary depending on the results of the clinical and diagnostic evaluation of the patient.

Interaction

The simultaneous use with drugs affecting the hemostatic system (direct and indirect anticoagulants, antiaggregants) is not recommended.

Special Instructions

A coagulogram should be performed before starting treatment. Use with caution during pregnancy and lactation (safety and efficacy not determined).

Contraindications

• Hemorrhagic diathesis and other diseases accompanied by a decrease in blood clotting.
• High sensitivity to sulodexide or any other components that make up the drug.
• Pregnancy.
• Lactation period.
• Childhood (due to lack of clinical experience).
  

Side effects

Dyspeptic symptoms (including nausea, vomiting), pain in the epigastrium, allergic reactions; pain, burning, bruising at the injection site.

Overdose

Symptoms: bleeding or bleeding.

Treatment: maintenance of vital functions (with withdrawal of the drug).

Similarities

Wessel Due F.